drugset / Trial / NCT02231905

Safety, Tolerability and Efficacy of Switching From Talipexole to Pramipexole in Patients With Parkinson's Disease

NCT02231905

Phase 4 Completed 29 enrolled Boehringer Ingelheim
NaSingle-groupOpen-labelTreatment

Summary

Study to assess the safety, tolerability and effectiveness of a switching from Domin® (talipexole) tablet to BI Sifrol® (pramipexole) tablet in patients with Parkinson's disease

Timeline

Start
2004-01
Primary completion
2004-11
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Pramipexole Unknown

Indications